Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults. In addition, studies have also shown that specialized pacemaking devices (DDD pacing) can improve conditions of HCM in children. However, growth of the body and organs, including the heart, is very rapid during childhood. Therefore the long-term effects of DDD pacing in children are unknown.

The purpose of this study is to examine the growth rate and nutrition of children with HCM. Due to this heart condition and the restrictions that are often placed on the child's activity level, children with HCM may grow at a slower rat and may have a greater tendency to be overweight.

Children participating in the study will have their growth rate and nutritional status measured before the study begins and throughout the course of the study.

Findings in this research study will not directly benefit the patients participating in it. However, information gathered as a result of this study may lead to improvements in the management of children with HCM in the future.

Condition	Treatment or Intervention	Phase
Hypertrophic Cardiomyopathy	Device: Paragon Pacemaker	Phase I

Further Study Details: 

Expected Total Enrollment:  100

Several studies have shown that dual chamber (DDD) pacemaker therapy relieves LV outflow obstruction and improves symptoms in most adult patients with obstructive hypertrophic cardiomyopathy (HCM). It is however, uncertain whether DDD pacing will be efficacious in children with obstructive HCM, because of evolving cardiac morphology and increased LV hypertrophy and outflow obstruction associated with rapid body growth. We propose to monitor clinical progress, and cardiac morphologic and hemodynamic changes over several years following implantation of a DDD pacemaker in children who present with obstructive HCM between the ages of 5 to 15 years. Functional status, myocardial ischemia, arrhythmias, and LV outflow obstruction will be evaluated by exercise tests, echocardiography, thallium scintigraphy, Holter monitoring, electrophysiologic and cardiac catheterization studies. The results of pacemaker therapy will be compared with the findings in a cohort of young patients with obstructive HCM who elect not to be treated with DDD pacemaker.

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA: DDD Pacemaker Therapy
Children of either gender, aged 5 to 15 years.
Presence of LV hypertrophy and LV outflow obstruction.
EXCLUSION CRITERIA: DDD Pacemaker Therapy
Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.
Chronic atrial fibrillation.
Positive pregnancy test.
INCLUSION CRITERIA: Cohort Study
Children of either gender, 5 to 20 years (children greater than 15 years will be included if there is access to reliable previous catheterization data).
Presence of LV hypertrophy and LV obstruction.
EXCLUSION CRITERIA: Cohort Study
Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization.
Chronic atrial fibrillation.
Positive pregnancy test.

Maryland
      National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States

Study ID Numbers:  940001; 94-H-0001
Record last reviewed:  October 7, 2004
Last Updated:  November 23, 2004
Record first received:  November 3, 1999
ClinicalTrials.gov Identifier:  NCT00001396
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08